Biochip Labs utilizes biochip technology to perform precise blood disorder diagnostics, specifically targeting conditions like sickle cell disease and thalassemia. Their testing services deliver accurate results that enable healthcare providers to make timely and informed treatment decisions for patients with these genetic disorders.
Funding
$150K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current diagnostic methods for blood disorders like sickle cell disease and thalassemia often lack the precision needed for comprehensive blood cell analysis, hindering timely and informed treatment decisions. Traditional blood rheology assays may not fully capture the complexities of blood cell behavior under physiological conditions. Existing methods may also fail to assess crucial factors such as blood cell adhesion and deformability, which are critical in understanding disease progression and therapeutic outcomes.
Solution
Biochip Labs offers a suite of comprehensive and functional biomarker assays utilizing biochip technology for in-depth blood testing. Their services provide accurate and quality testing for blood disorders, including sickle cell disease and thalassemia, by analyzing blood cell adhesion, deformability, and whole blood rheology. The assays employ microfluidic platforms to mimic physiological conditions, offering a more detailed understanding of blood cell behavior. By combining traditional and proprietary laboratory testing methods, Biochip Labs delivers precise blood disorder diagnostics that enable healthcare providers and researchers to make well-informed decisions.
Target Audience
Biochip Labs serves research centers, clinical care providers, pharmaceutical companies, and other laboratories requiring accurate and comprehensive blood disorder diagnostics.
Features
- Adhesion BioChip: Analyzes blood cell adhesion to immobilized proteins under physiologic flow.
- OcclusionChip: Assesses red blood cell deformability through a series of microcapillary networks.
- Endothelium-on-a-chip: Evaluates blood cell adhesion to the endothelium under physiologic flow.
- RheologyChip: Simultaneously analyzes whole blood rheology and blood cell adhesion.
- Hypoxia Assay: Analyzes blood cell adhesion, RBC deformability, and whole blood rheology under low oxygen tension.
- Traditional Blood Rheology Assays: Offers traditional assays for whole blood and RBC rheology analysis.
- Microfluidic assay combined with micro particle image velocimetry technique for integrated assessment of whole blood viscosity (WBV) and RBC adhesion.
- Standardized in vitro microfluidic assay and Occlusion Index (OI) for the assessment of red blood cell (RBC)–mediated microcapillary occlusion.